Molecular analysis for cancer patients at Gustave Roussy
Gustave Roussy Cancer Profiling
This study is testing a way to find specific genetic changes in cancer patients to see if they can get targeted treatments that might work better for them.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 20000 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Gustave Roussy, Cancer Campus, Grand Paris Academic / other |
| Locations | 4 sites (Villejuif, Val de Marne and 3 other locations) |
| Trial ID | NCT04932525 on ClinicalTrials.gov |
What this trial studies
The STING study aims to conduct high throughput molecular analysis, including next generation sequencing and immunological profiling, to identify patients with cancer who have targetable genomic alterations. This multicenter study will explore the mechanisms of sensitivity and resistance to anti-cancer treatments. Patients identified with actionable alterations may be eligible for subsequent clinical trials at Gustave Roussy or other participating centers.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 18 and older with solid tumors or hematological malignancies.
Not a fit: Patients who are minors, pregnant, or unable to provide informed consent will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to more personalized and effective treatment options for cancer patients based on their unique genetic profiles.
How similar studies have performed: Other studies utilizing similar high throughput molecular profiling approaches have shown promise in identifying actionable targets in cancer treatment.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Age ≥ 18 years 2. Histology: solid malignant tumor or hematological malignancy. 3. Patient with a social security in compliance with the French law relating to biomedical research (Article L.1121-11 of French Public Health Code) 4. Voluntary signed and dated written informed consent prior to any study specific procedure. Exclusion Criteria: 1. Any condition which in the Investigator's opinion makes it undesirable for the subject to participate in a clinical trial or which would jeopardize compliance with the protocol 2. Patient under guardianship or deprived of his liberty by a judicial or administrative decision or incapable of giving its consent 3. Pregnant or breast-feeding women 4. Minors (Age \< 18 years)
Where this trial is running
Villejuif, Val de Marne and 3 other locations
- Gustave Roussy Cancer Campus Grand Paris — Villejuif, Val de Marne, France (Recruiting)
- Hôpital Marie-Lannelongue — Le Plessis-Robinson, France (Recruiting)
- Hôpital Saint-Joseph — Paris, France (Not_yet_recruiting)
- Hôpital Foch — Suresnes, France (Not_yet_recruiting)
Study contacts
- Principal investigator: Antoine Italiano, MD PhD — Gustave Roussy, Cancer Campus, Grand Paris
- Study coordinator: Antoine Italiano, MD PhD
- Email: antoine.italiano@gustaveroussy.fr
- Phone: +33 (0)1 42 11 42 11
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.